[HTML] frontiersin.org

[HTML][HTML] Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go

K Wang, C Wang, H Jiang, Y Zhang, W Lin… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …
被引用次数：51 相关文章

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

K Wang, C Wang, H Jiang, Y Zhang… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.

K Wang, C Wang, H Jiang, Y Zhang, W Lin… - Frontiers in …, 2021 - europepmc.org
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …
[HTML] nih.gov

[HTML][HTML] Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

K Wang, C Wang, H Jiang, Y Zhang, W Lin… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …